Ani pharmaceuticals head of rare disease sells $30k in stock

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Iran conflict latest: Hegseth says Iran conflict has "only just begun" Nasdaq ends more than 1% higher as solid economic data lifts spirits Gold prices rebound from previous session’s hefty drop, helped by weaker dollar Oil ticks up in seesaw trade as escalating Middle East conflict remains in focus (South Africa Philippines Nigeria) Ani pharmaceuticals head of rare disease sells $30k in stock By Insider Trading Published 03/04/2026, 06:55 PM Ani pharmaceuticals head of rare disease sells $30k in stock 0 ANIP 0.56% Christopher Mutz, Head of Rare Disease at ANI PHARMACEUTICALS INC (NASDAQ:ANIP) , sold 417 shares of common stock on March 2, 2026, at a price of $74. The total value of the transaction amounted to $30,858. The sale came as shares traded near $76.53, with the company showing strong fundamentals including 44% revenue growth and a market cap of $1.6 billion. Following the transaction, Mutz directly owns 103,508 shares of ANI PHARMACEUTICALS INC. The sale was executed under a Rule 10b5-1 trading plan adopted on June 16, 2025. According to InvestingPro analysis, ANIP appears undervalued at current levels, with analysts forecasting EPS of $9.41 for FY2026. The platform’s comprehensive Pro Research Report offers deeper insights into the company’s growth trajectory. In other recent news, ANI Pharmaceuticals Inc. reported a robust financial performance for the fourth quarter of 2025, surpassing market expectations. The company achieved an earnings per share of $2.33, outperforming the forecasted $1.97, which represents an 18.27% surprise. Additionally, ANI Pharmaceuticals reported revenue of $247.1 million, exceeding the anticipated $232.37 million. These results highlight the company’s strong financial health and operational efficiency. Despite the positive earnings report, the stock experienced a slight premarket decline. There were no updates regarding mergers or acquisitions. Analyst firms have not rec...